WO1994018993A1 - Composition therapeutique a base d'herbes - Google Patents

Composition therapeutique a base d'herbes Download PDF

Info

Publication number
WO1994018993A1
WO1994018993A1 PCT/US1994/002183 US9402183W WO9418993A1 WO 1994018993 A1 WO1994018993 A1 WO 1994018993A1 US 9402183 W US9402183 W US 9402183W WO 9418993 A1 WO9418993 A1 WO 9418993A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
present
composition
weight
root
Prior art date
Application number
PCT/US1994/002183
Other languages
English (en)
Inventor
Johel M. Neiron
Original Assignee
Pharmakon Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakon Usa, Inc. filed Critical Pharmakon Usa, Inc.
Priority to AU62523/94A priority Critical patent/AU6252394A/en
Publication of WO1994018993A1 publication Critical patent/WO1994018993A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the subject invention relates to a therapeutic herbal composition which is potentially beneficial for immune enhancement, prophylaxis and treatment of cancer, AIDS, Epstein Barr syndrome, depression and the like, and as a blood tonic.
  • the Australian Therapeutic Goods Administration has approved this therapeutic composition for use as a blood tonic.
  • HIV human immunodeficiency virus
  • the virus preferentially targets the helper T cells, which play a central role in the functioning of the immune system. In most cases the virus, once incorporated into the helper T cell, remains dormant for an unspecified period of time. Once activated, however, the virus rapidly destroys the helper T cells, thereby crippling the immune system. It is at this stage that the symptoms of AIDS become evident. These include: o enlarged lymphoid glands o unexplained rapid weight loss and diarrhoea o fever and night sweats o dermatitis and skin eruptions and lesions o diminished sensitivity to skin tests o memory disorder and behavioral changes o increased incidence of certain cancers. A common tumor of AIDS patients is Kaposi's sarcoma, resulting in purplish marks on the skin, o increased susceptibility to opportunistic infections that rarely infect normal individuals.
  • Turmeric extract prepared from Curcuma longa was shown in Japanese Patent Publication No. 4,095,032 to stimulate transdermal absorption and to increase the effect of pharmacologically active components.
  • Japanese Publication No. 4,091,029 describes the combination of Curcoma longa and Cinnamomum cassia to obtain a similar effect.
  • Japanese Patent Publication No. 4,005,237 teaches the combination of Cinnamomum sieboldii and Allium sativum for superoxide scavenging in the treatment of inflammatory disorders.
  • 3,724,341 teaches the use of Cinnamomum zeylanicum as an anti-inflammatory agent which exerts a synergistic anti-inflammatory effect in combination with Pumica granitum cortex, Cardamon zingiberaceie fruit and Piper longum fruit.
  • Japanese Patent Publication No. 2,069,431 discloses the use of Curcuma longa for use as an antioxidant in foods and pharmaceutical products.
  • German Patent Publication No. 1,767,469 teaches the use of Allium sativum for use in preparations having an anti- cancer, anti-bacterial and chemotherapeutic effect.
  • compositions useful in enhancing the immune system there exists a great need for therapeutic compositions useful in enhancing the immune system.
  • the composition of herbs described herein functions to augment the immune system through the synergistic interaction of the herbal components, and thus represents a potential tool in the treatment of cancer, AIDS, Epstein Barr virus and depression, as well as a general blood tonic.
  • the subject invention provides a therapeutic composition
  • a therapeutic composition comprising Boswelia carterii stem resin, Styrax benzoin stem resin, Cinnamomum zeylanicum bark, Curcuma zedoaria root, Syzygium aromaticum fruit, Nardostachys chinensis root, Betula alba bark, Impatiens balsamina bark, Costus spicatus root, Allilum sativum bulb and Cyperu ⁇ rotundus root in amounts effective to produce a physiological benefit.
  • the subject composition comprises the eleven plants of the following list for typical administration: wt. % bv wt. Ran ⁇ e fwt. %.
  • Boswelia carterii stem resin 90 mg 15.5 1.5 - 75
  • Styrax benzoin stem resin 90 mg 15.5 1.5 - 75
  • Curcuma zedoaria root 35 mg 6.0 0.6 - 30
  • Syzygium aromaticum fruit 35 mg 6.0 0.6 - 30 Nardostachys chinensis root 35 mg 6.0 0.6 - 30
  • Betula alJba bark 90 mg 5.5 1.5 - 75
  • Impatiens balsamina bark 90 mg 5.5 1.5 - 35
  • Allilum sativum bulb 25 mg 4.3 0.4 - 25
  • Cyperus rotundus root 25 mq 4.3 0.4 - 25
  • the above herbs are typically dried and ground to a fine powder. All weights are expressed in milligrams and all percentages are by weight of the essential elements in the composition.
  • the composition is typically an intimate mixture of powders. However, extracted herbs may also be used.
  • the known biological active components include choline and thiamine. Under normal conditions a 580 mg dose would be administered several times daily. The dosage of course may vary depending on body weight and other conditions readily determinable by those skilled in the art who have read the subject application. Administration is typically oral, with administration being via a capsule. In addition to the above herbs, various fillers, such as ash, may be present.
  • a unique natural composition derived from plant extracts has been demonstrated to overcome many of the debilitating symptoms of AIDS.
  • This composition which is typically orally ingested, represents a breakthrough in the pharmaceutical management of AIDS patients. Pilot studies have demonstrated that the subject composition causes: o reversal of gland swelling o restoration of feeling of well being and associated weight gain o improvement in response to skin hypersensitivity tests o increase in the circulating concentration of helper T cells (CD4-positive cells) . Associated with this is an improvement in the CD4/CD8 ratio, with many patients returning to a normal ratio.
  • the optimal time for therapy with the subject composition should commence in relation to the first appearance of symptoms, or may be used as a prophylactic prior to any indications.
  • composition Four capsules of the subject composition were taken orally twice daily (morning and evening) , one hour before meals.
  • the composition was shown to be a low toxicity product capable of dramatically elevating the population of helper T cells.
  • Detailed hematological and biochemical tests were conducted on each patient, the most significant data are presented in Table 1.
  • the mean CD4/CD8 ratio (ratio of helper T cells to cytotoxic T cell and suppressor T cells) at the commencement of treatment was 0.42 ⁇ 0.08. (Note: The ratio in a healthy population is 1.0 - 3.5.) After a treatment period ranging from 2-23 months the CD4/CD8 ratio had significantly increased by two-fold to 0.84 ⁇ 0.14 (p ⁇ 0.001). Concurrently with this change was an improvement in the response to skin hypersensitivity tests and a general increase in well-being. This latter effect is demonstrated by the overall restoration of body weight, increasing from 62.9 to 70.1 kg, a weight gain of 7.2 kg (p ⁇ 0.001) .
  • lymphocytes are found in large numbers in the blood and the lymph (the colorless fluid inthe lymphatic vessels that connect the lymph nodes of the body) and in specialized lymphoid organs, such as the thymus, lymph nodes, spleen, tonsils and appendix. Lymphocytes can be separated into two major classes based on the type of immune response.
  • B cells and T cells arise from common stem cells in the bone marrow.
  • lymphocytes When produced in the bone marrow, lymphocytes are immature and require further processing in order to become mature, functional cells.
  • some cells differentiate within the bone marrow to become B cells, whereas others are processed in the thymus to generate T cells.
  • antigens Binding of an antigen transforms a B cell into a plasma cell, which is responsible for humoral or antibody-mediated immunity.
  • the plasma cell produces and secretes antibodies which bind to an invading cell, either causing it to be inactivated or targeting it for removal from the body.
  • the effector cell can kill a virus-infected host cell that has viral proteins on its surface, thereby eliminating the infected cell before the virus has replicated. In other situations the reacting cell activates macrophages to destroy the foreign microorganism.
  • the cell-mediated immune response is also responsible for the rejection of skin grafts and organ transplants.
  • the main function of the immune system is to save us from disease-causing microorganisms, the system cannot actually distinguish between pathogenic and non- pathogenic organisms. Rather, it is because they are recognized as foreign (or non-self) that our immune system is induced to react against them.
  • B cells Before B cells differentiate to mature antibody-secreting cells, called plasma cells, they carry their antibodies as membrane-bound surface molecules. These antibodies act as cell-surface receptors for antigens, thereby providing a means of distinguishing foreign invading cells from the body's own cells.
  • an antigen associated with a bacteria, virus, etc.
  • the specific binding together with other cellular interactions, triggers the proliferation and maturation of that particular B cell.
  • the resultant plasma cells secrete antibodies of the same specificity as the original antibody on the surface of the immature B cell.
  • clonal selection The process whereby antigens stimulate division and maturation of B cells to which they bind is referred to as clonal selection.
  • This term is derived from the proposal that the immune system contains many millions of different families, or clones, of B cells each committed to make one particular antibody. The presence of a foreign antigen is immediately recognized by one (or more) of these millions of clones, and those that react with the antigen are induced to proliferate and mature. Each cell produced from a clone therefore produces the same antibody and this leads to a build-up of the specific antibody. These antibody molecules are then directed against the foreign antigen. If the foreign antigen is toxic, binding of antibody generally inactivates the toxin. If it is an invading microorganism, antibody binding leads to destruction of the microorganism.
  • helper T cells T H cells
  • the helper T cells respond by releasing growth factors, called interleukins (or lymphokines) , which stimulate cell division and maturation of the B cells, ultimately inducing the production of memory cells and plasma cells, which are specialized for producing large quantities of antibodies.
  • T lymphocytes are involved in two very different types of cellular immune responses. One is to destroy cells that contain foreign antigens on their surface, as occurs when a host cell becomes infected with a virus. Thus, often the target cells are an individual's own cells shortly after they have become infected by a virus. The cells responsible for this response are referred to as cytotoxic T cells. Because viruses proliferate within cells, where they are protected from attack by antibodies, the cytotoxic T cells provide an important defense against the spreading of the viral infection to other cells, by destroying the infected cell before virus proliferation and assembly has occurred. Cytotoxic T cells are also responsible for the rejection of skin grafts and organ transplants.
  • the cell When an antigen binds to the immature T cell via specific cell-surface receptors, the cell is transformed into a lymphoblast which divides to produce a population of activated T cells. These T cells subsequently differentiate to produce cytotoxic T cells, memory cells, helper T cells
  • T H cells and suppressor T cells (T s cells) .
  • T s cells suppressor T cells
  • the T H cells are critical in facilitating the response of both B cells (as discussed earlier) and the cytotoxic T cells. As a consequence, any reduction in the circulating level of T H cells leads to a dramatically impaired immune response.
  • the T s cells have the opposite effect by blocking B and T cell responses.
  • cytotoxic T cells and B cells are the cells directly responsible for the immune responses against infection, their effectiveness in the elimination of the infection is dramatically modulated by the relative level of helper T cells and suppressor T cells in the blood.
  • T lymphocytes are small, round cells which are not readily distinguishable under the microscope. They can be identified, however, by the presence of specific glycoproteins that are present on their surface (see Table 2) . Whereas all T cells have the CD3 glycoprotein, only helper T cells have the CD4 glycoprotein and both cytotoxic T cells and suppressor T cells have the CD8 glycoprotein. The importance of these differences is that they can be used to determine the relative concentration of the various types of T cells. For instance, the CD4/CD8 ratio can be used to determine the concentration of helper T cells relative to the concentration of both the cytotoxic and suppressor T cells.
  • T s Suppressor T cells
  • T H cell The host cell for the human immunodeficiency virus (HIV) is the helper T cell (T H cell) .
  • T H cell The helper T cell
  • the disease is transmitted when a T H cell, infected by the virus, is transferred through the blood or via semen or vaginal secretions, to an uninfected individual.
  • the T H cells of that individual immediately recognize the virus-infected cell as foreign.
  • the foreign HIV particles have bound to the T H cells, been incorporated into the cells and rendered them inactive.
  • the virus is surrounded by a lipid bilayer membrane containing two glycoproteins, one of which binds tightly to the CD4 protein on the membrane of the T H cells.
  • the virus As the virus is transferred from one T H cell to another in the infected individual, an increasing proportion of the immune system is disabled, since the cells that are essential for mounting an immune response are rapidly being destroyed.
  • the HIV virus may lie dormant inside the infected T H cells for some time. However, once stimulated, the proliferation of the virus-infected cells overwhelms the remaining uninfected T H cells and the immune system is rapidly rendered ineffective.
  • the depletion of the T H cell population can be clinically evaluated by measuring the CD4/CD8 ratio, which is a measure of the T H cell population relative to that of the cytotoxic T cells and the T s cells.
  • the entire immune system is rendered quite inactive.
  • the infected individual is then prone to a greater incidence of certain cancers and to infection by other opportunistic microorganisms. It is this latter effect that frequently leads to the death of the infected person.
  • the subject composition by being able to elevate the T H cell population, has the potential to prolong the life of AIDS sufferers by restoring the T cell profile to normal levels.
  • the mean hemoglobin concentration was 11.19 g/dL at the commencement of treatment, but was significantly elevated (p ⁇ 0.001) to 14.3 g/dL after a treatment period (a 20.4% increase) .
  • the subject powder maintains a brown color and does not lose its character under the cycling effect of night and day. Smell and taste are unimpaired during storage.
  • Alternative solubility of the subject composition in organic solvents e.g. dichloromethane, chloroform and ethyl alcohol at room temperature and at 40°, 60° and 70°C, identify the product with a dissolution rate of 26-56%.
  • the batches are sterilized within radiation or by ethylene oxide, the stability records show a lack of detectable amounts of degradation products and systematic bacteriological tests under conditions of high humidity proved satisfactory.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Une composition thérapeutique à base d'herbes est bénéfique pour fortifier le système immunitaire et traiter une grande variété de maladies telles que le cancer, le SIDA, le syndrome d'Epstein Barr et la dépression. Cette composition est également utile comme tonique sanguin. Cette composition comprend la combinaison synergique de résine de tige $(Boswelia carterii), la résine de tige Styrax benzoin, l'écorce Cinnamomum zeylanicum, la racine Curcuma zedoaria, le fruit Syzygium aromaticum, la racine Nardostachys chinensis, l'écorce Betula alba, l'écorce Impatiens balsamina, la racine Costus spicatus, le bulbe Allilum sativum et la racine Cyperus rotundus.
PCT/US1994/002183 1993-02-23 1994-02-23 Composition therapeutique a base d'herbes WO1994018993A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62523/94A AU6252394A (en) 1993-02-23 1994-02-23 Therapeutic herbal composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2056193A 1993-02-23 1993-02-23
US08/020,561 1993-02-23

Publications (1)

Publication Number Publication Date
WO1994018993A1 true WO1994018993A1 (fr) 1994-09-01

Family

ID=21799296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002183 WO1994018993A1 (fr) 1993-02-23 1994-02-23 Composition therapeutique a base d'herbes

Country Status (2)

Country Link
AU (1) AU6252394A (fr)
WO (1) WO1994018993A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747057A2 (fr) * 1995-06-09 1996-12-11 Pecchiai, Maria Enrica Utilisation d'essances aromatiques et exudats de plantes, en particulier dans les domaines médicaux, zootechnique et agronomique
EP0753305A1 (fr) * 1995-07-13 1997-01-15 Showa Shell Sekiyu Kabushiki Kaisha Composition anti-SIDA et procédé de traitement d'infections à VIH avec un agent anti-VIH contenant un médicament brut
AU706653B2 (en) * 1995-03-01 1999-06-17 L'oreal Hair dye composition containing a product of grinding plants or parts of plants of the species impatiens balsamina, and its application
WO2002062364A1 (fr) * 2001-02-05 2002-08-15 Gbodossou Erick Vidjin Agnih Composition antivirale a base de plantes medicinales pour combattre le vih/sida
WO2003006036A2 (fr) * 2001-07-11 2003-01-23 Sahajanand Biotech Private Limited Preparation a base de plantes
WO2004112692A2 (fr) * 2003-05-19 2004-12-29 Amazon Biotech Inc. Compositions therapeutiques a base de plantes medicinales
WO2005030232A2 (fr) * 2003-07-14 2005-04-07 Shambabu Ayare Compositions a base d'herbes pour le traitement du sida, leur mode de preparation, et methode de traitement de patients
US7160561B2 (en) 2003-05-19 2007-01-09 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
WO2014112663A1 (fr) * 2013-01-17 2014-07-24 주식회사 한국전통의학연구소 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200186A (en) * 1989-08-11 1993-04-06 Inverni Della Beffa S.P.A. Process for the preparation of extracts having high content in anthocyanosides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200186A (en) * 1989-08-11 1993-04-06 Inverni Della Beffa S.P.A. Process for the preparation of extracts having high content in anthocyanosides

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU706653B2 (en) * 1995-03-01 1999-06-17 L'oreal Hair dye composition containing a product of grinding plants or parts of plants of the species impatiens balsamina, and its application
EP0747057A2 (fr) * 1995-06-09 1996-12-11 Pecchiai, Maria Enrica Utilisation d'essances aromatiques et exudats de plantes, en particulier dans les domaines médicaux, zootechnique et agronomique
EP0747057A3 (fr) * 1995-06-09 1998-07-08 Pecchiai, Maria Enrica Utilisation d'essences aromatiques et exudats de plantes, en particulier dans les domaines médical, zootechnique et agronomique
EP0753305A1 (fr) * 1995-07-13 1997-01-15 Showa Shell Sekiyu Kabushiki Kaisha Composition anti-SIDA et procédé de traitement d'infections à VIH avec un agent anti-VIH contenant un médicament brut
WO2002062364A1 (fr) * 2001-02-05 2002-08-15 Gbodossou Erick Vidjin Agnih Composition antivirale a base de plantes medicinales pour combattre le vih/sida
WO2003006036A3 (fr) * 2001-07-11 2004-05-27 Sahajanand Biotech Private Ltd Preparation a base de plantes
WO2003006036A2 (fr) * 2001-07-11 2003-01-23 Sahajanand Biotech Private Limited Preparation a base de plantes
US6780441B2 (en) 2001-07-11 2004-08-24 Sahajanand Biotech Private Limited Composition of eleven herbals for treating cancer
WO2004112692A2 (fr) * 2003-05-19 2004-12-29 Amazon Biotech Inc. Compositions therapeutiques a base de plantes medicinales
WO2004112692A3 (fr) * 2003-05-19 2005-08-04 Amazon Biotech Inc Compositions therapeutiques a base de plantes medicinales
US7160561B2 (en) 2003-05-19 2007-01-09 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
WO2005030232A2 (fr) * 2003-07-14 2005-04-07 Shambabu Ayare Compositions a base d'herbes pour le traitement du sida, leur mode de preparation, et methode de traitement de patients
WO2005030232A3 (fr) * 2003-07-14 2006-03-02 Shambabu Ayare Compositions a base d'herbes pour le traitement du sida, leur mode de preparation, et methode de traitement de patients
WO2014112663A1 (fr) * 2013-01-17 2014-07-24 주식회사 한국전통의학연구소 Composition pharmaceutique pour prévenir et traiter la pancréatite chronique comprenant un extrait de nardostachys jatamansi en tant que substance active

Also Published As

Publication number Publication date
AU6252394A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
Loha et al. Acute and subacute toxicity of methanol extract of Syzygium guineense leaves on the histology of the liver and kidney and biochemical compositions of blood in rats
Barnes et al. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties
DE69738535T2 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
Brendler et al. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae)
Kosasih et al. Hepatoprotective effect of citrus sinensis peel extract against isoniazid and rifampicin-induced liver injury in wistar rats
WO1994018993A1 (fr) Composition therapeutique a base d'herbes
WO2004112692A2 (fr) Compositions therapeutiques a base de plantes medicinales
Sivakumar et al. Phytochemical analysis, Antioxidant and Antiarthritic activities of different solvent extract of Aegle marmelos L. unripe fruit
US5980903A (en) Composition for the treatment of viral infections including HIV
US7160561B2 (en) Herbal composition and method of treating HIV infection
US20040258712A1 (en) Herbal composition containing sea salt
Gbolade Nigerian Medicinal Plants with Antisnake Venom Activitiy-Review
Kumar et al. Scope for utilization of Curcuma longa, Embelica officinales and Tinospora cordifolia for human health in COVID-19 like scenario in Himachal Pradesh, India
US20040234546A1 (en) Treatments using an herbal composition
AU760967B2 (en) Herbal composition for the prophylaxis and treatment of AIDS
Shivakoti et al. Preliminary phytochemical screening of Setaria verticillata
ZA200604983B (en) Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences
US5091181A (en) Asphodelus composition for increasing white blood cell count
JPH0987195A (ja) 生薬を含有する抗エイズウイルス剤
IF et al. Hepatoprotective potential and histological studies of effects of Celosia Argentea L. on Paracetamol-Induced Liver Damage
Oriakhi et al. ACUTE AND SUB CHRONIC TOXICITY PROFILE OF METHANOL EXTRACT OF TETRACARPIDIUM CONOPHORUM SEEDS ON WISTAR ALBINO RATS
US20020006446A1 (en) Botanical combinations for treating AIDS and immune-deficient patients to maintain good health and the process for preparing the same
KR100977583B1 (ko) 불미나리에서 간세포 보호 및 간손상 예방 효능을 갖는카페익산을 추출하는 방법 및 이를 포함하는 기능성건강지향식품
Elujoba et al. The effects of a mixture of extracts from indigenous herbs on HIV/AIDS patients employing CD4+ T lymphocyte counts and viral load reductions as assessment indices
Eidangbe et al. Attenuation of Carbon Tetrachloride—Induced Hepatoxicity by Dacryodes edulis Seeds Ethanolic Extract in Male Wistar Rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA